MVD, assessed by CD105 immunostaining, has been suggested as a quantitative measure of tumoral angiogenesis and has been reported as a prognostic indicator of outcome in malignant tumors, including HCC 7. This evidence concerns the gene ENG and hepatocellular carcinoma.